The board of Biogen (NASDAQ:BIIB) has authorized the repurchase of up to an additional $5B of its outstanding common stock. All reacquired shares will be retired.
The share buy back program authorized in March is still in effect.
Shares up 1% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.